{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:48:05Z","timestamp":1761598085184,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clineuro.2019.105390","type":"journal-article","created":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T09:29:50Z","timestamp":1560677390000},"page":"105390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal"],"prefix":"10.1016","volume":"184","author":[{"given":"Filipa","family":"Ladeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Braz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraia","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"F\u00e9lix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Sofia","family":"Correia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Martins da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasco","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Vale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9 de","family":"S\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Capela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.clineuro.2019.105390_bib0005","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","article-title":"Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis","volume":"73","author":"McCormack","year":"2013","journal-title":"Drugs"},{"issue":"May (5)","key":"10.1016\/j.clineuro.2019.105390_bib0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/14737175.2016.1168295","article-title":"Disease activity return after natalizumab cessation in multiple sclerosis","volume":"16","author":"Rasenack","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.clineuro.2019.105390_bib0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10072-013-1527-1","article-title":"Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up","volume":"35","author":"Melis","year":"2014","journal-title":"Neurol. Sci."},{"issue":"August (8)","key":"10.1016\/j.clineuro.2019.105390_bib0020","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00415-016-8162-8","article-title":"Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors","volume":"263","author":"Zurawski","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2019.105390_bib0025","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1212\/NXI.0000000000000297","article-title":"Risk of relapse after natalizumab withdrawal - results from the French TYSEDMUS cohort","volume":"3","author":"Papeix","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2019.105390_bib0030","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE- a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2019.105390_bib0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol. Ther."},{"issue":"June (6)","key":"10.1016\/j.clineuro.2019.105390_bib0040","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"July (1)","key":"10.1016\/j.clineuro.2019.105390_bib0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod - A randomized, placebo controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"December (12)","key":"10.1016\/j.clineuro.2019.105390_bib0050","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3109\/00207454.2015.1127919","article-title":"Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod","volume":"126","author":"Evangelopoulos","year":"2016","journal-title":"Int. J. Neurosci."},{"issue":"September (9)","key":"10.1016\/j.clineuro.2019.105390_bib0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2015-312221","article-title":"Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation","volume":"87","author":"Weinstock-Guttman","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"May (22)","key":"10.1016\/j.clineuro.2019.105390_bib0060","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O\u2019Connor","year":"2011","journal-title":"Neurology"},{"issue":"August (8)","key":"10.1016\/j.clineuro.2019.105390_bib0065","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","article-title":"Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)","volume":"71","author":"Clerico","year":"2014","journal-title":"JAMA Neurol."},{"issue":"September (9)","key":"10.1016\/j.clineuro.2019.105390_bib0070","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2014-307591","article-title":"Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis","volume":"85","author":"Gueguen","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"September (9)","key":"10.1016\/j.clineuro.2019.105390_bib0075","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","article-title":"De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate","volume":"258","author":"Havla","year":"2011","journal-title":"J. Neurol."},{"issue":"September (1-2)","key":"10.1016\/j.clineuro.2019.105390_bib0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jns.2011.05.043","article-title":"Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients","volume":"308","author":"Kerbrat","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"February (2)","key":"10.1016\/j.clineuro.2019.105390_bib0085","first-page":"186","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch. Neurol."},{"issue":"November (11)","key":"10.1016\/j.clineuro.2019.105390_bib0090","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult. Scler."},{"issue":"August (2)","key":"10.1016\/j.clineuro.2019.105390_bib0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ane.12250","article-title":"What to expect after natalizumab cessation in a real-life setting","volume":"130","author":"Salhofer-Polanyi","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"May (6)","key":"10.1016\/j.clineuro.2019.105390_bib0100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: predictive factors","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.clineuro.2019.105390_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.671","article-title":"Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation","volume":"7","author":"Gonz\u00e1lez\u2010Suarez","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.clineuro.2019.105390_bib0110","first-page":"1","article-title":"Switching patients at high risk of PML from natalizumab to another disease-modifying therapy","volume":"0","author":"Giovannoni","year":"2016","journal-title":"Pract. Neurol."},{"issue":"November (Pt. 11)","key":"10.1016\/j.clineuro.2019.105390_bib0115","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain"},{"issue":"May (5)","key":"10.1016\/j.clineuro.2019.105390_bib0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","article-title":"Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study","volume":"19","author":"Borriello","year":"2012","journal-title":"Eur. J. Neurol."},{"issue":"February (1-2)","key":"10.1016\/j.clineuro.2019.105390_bib0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2013.11.031","article-title":"JCV epidemiology in MS (JEMS) - epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients - Portuguese data","volume":"337","author":"Da Silva","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"July-August (4)","key":"10.1016\/j.clineuro.2019.105390_bib0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.20344\/amp.5032","article-title":"Multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort. (2014)","volume":"27","author":"Carvalho","year":"2014","journal-title":"Acta Med. Port."},{"issue":"November (9)","key":"10.1016\/j.clineuro.2019.105390_bib0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.33588\/rn.5909.2013479","article-title":"The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study","volume":"59","author":"Sousa","year":"2014","journal-title":"Rev Neurol."},{"issue":"50 (1)","key":"10.1016\/j.clineuro.2019.105390_bib0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"issue":"February (2)","key":"10.1016\/j.clineuro.2019.105390_bib0145","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"August (5)","key":"10.1016\/j.clineuro.2019.105390_bib0150","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1212\/NXI.0000000000000388","article-title":"\u03b14-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846719301866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846719301866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:30:17Z","timestamp":1759588217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846719301866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"alternative-id":["S0303846719301866"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2019.105390","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2019.105390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105390"}}